Aricept, Donepezil Newswire

Aricept, Donepezil Newswire

Comprehensive Real-Time News Feed for Aricept, Donepezil (generic).

Results 1 - 20 of 124 in Aricept, Donepezil (generic)

  1. Alzheimer's drug shouldn't be prescribed for cognitive impairment, without genetic testRead the original story w/Photo

    Saturday | Newkerala.com

    Washington D.C. [US], Feb. 26 : US researchers have warned, Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment, without a genetic test. Researchers from the University Of California discovered that for people who carry a specific genetic variation, the K-variant of butyrylcholinesterase, or BChE-K donezpezil, could accelerate cognitive decline.

    Comment?

  2. Alzheimer's drug prescribed off-label could accelerate cognitive decline for some patientsRead the original story w/Photo

    Friday Feb 24 | Medical News

    Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation -- the K-variant of butyrylcholinesterase, or BChE-K -- donezpezil could accelerate cognitive decline.

    Comment?

  3. Alzheimer's Drug Prescribed 'Off-Label' for Mild Cognitive Impairment Could Pose Risk for SomeRead the original story

    Friday Feb 24 | Newswise

    FINDINGS Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation - the K-variant of butyrylcholinesterase, or BChE-K - donezpezil could accelerate cognitive decline.

    Comment?

  4. Alzheimer's drug prescribed off-label could pose risk for someRead the original story w/Photo

    Thursday Feb 23 | EurekAlert!

    Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation -- the K-variant of butyrylcholinesterase, or BChE-K -- donezpezil could accelerate cognitive decline.

    Comment?

  5. Cilostazol as an add-on therapy for patients with Alzheimer's...Read the original story w/Photo

    Wednesday Feb 22 | BioMed Central

    We explored the therapeutic responses by using a case-control study, which was conducted in Taiwan. We enrolled 30 participants with stable AD who were receiving cilostazol twice per day as an add-on therapy combined with AChEIs, and 30 participants as controls who were not receiving cilostazol as an add-on therapy.

    Comment?

  6. 5 Interesting Medication Case Reports - Part 2Read the original story w/Photo

    Sunday Feb 5 | Pharmacy Times

    This article is part 2 of a 6-part series on interesting and unusual medication-related case reports. For part 1 click here .

    Comment?

  7. Open Clinical Trials For Alzheimer's DrugRead the original story

    Wednesday Feb 15 | Town Topics

    A drug that could bring hope to millions of people living with Alzheimer's disease is being tested in clinical trials by a Monmouth Junction-based pharmaceutical company at research sites in Mercer, Monmouth and Ocean counties.

    Comment?

  8. Dementia to-do listRead the original story w/Photo

    Saturday Feb 11 | Castanet.net

    Finding out you have dementia can be upsetting and frightening for the person with dementia, the caregiver and the family. Your hopes and dreams for the future may seem unattainable; you may feel helpless, hopeless and lost, but what you need to know is that you are not alone, and it is still possible to live a good life with dementia.

    Comment?

  9. Diagnosis to-do listRead the original story w/Photo

    Saturday Feb 11 | Castanet.net

    Finding out you have dementia can be upsetting and frightening for the person with dementia, the caregiver and the family. Your hopes and dreams for the future may seem unattainable; you may feel helpless, hopeless and lost, but what you need to know is that you are not alone, and it is still possible to live a good life with dementia.

    Comment?

  10. Anavex Life Sciences Corp. (AVXL) Now Covered by Analysts at Noble FinancialRead the original story w/Photo

    Tuesday Feb 7 | AmericanBankingNews.com

    The brokerage set a "buy" rating and a $16.00 price target on the stock. Noble Financial's price target would suggest a potential upside of 213.73% from the stock's previous close.

    Comment?

  11. Anavex Life Sciences Corp. (AVXL) to Release Quarterly Earnings on MondayRead the original story w/Photo

    Friday Feb 3 | IntersportsWire

    Shares of Anavex Life Sciences Corp. traded down 0.0655% on Friday, hitting $4.7319. 273,647 shares of the stock traded hands.

    Comment?

  12. Zacks: Anavex Life Sciences Corp. (AVXL) Given $12.50 Average Price Target by BrokeragesRead the original story w/Photo

    Sunday Jan 29 | IntersportsWire

    Anavex Life Sciences Corp. has received a consensus broker rating score of 1.00 from the two brokers that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.

    Comment?

  13. Translational models for vascular cognitive impairment: a review including larger speciesRead the original story w/Photo

    Jan 24, 2017 | BioMed Central

    Disease models are useful for prospective studies of pathology, identification of molecular and cellular mechanisms, pre-clinical testing of interventions, and validation of clinical biomarkers. Here, we review animal models relevant to vascular cognitive impairment .

    Comment?

  14. Zacks: Anavex Life Sciences Corp. (AVXL) Given Consensus...Read the original story w/Photo

    Jan 24, 2017 | AmericanBankingNews.com

    Shares of Anavex Life Sciences Corp. have been given a consensus broker rating score of 1.00 from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

    Comment?

  15. Using Advanced Analytics to Develop New Therapeutic Approaches for Complex Neurodegenerative DiseasesRead the original story

    Jan 19, 2017 | US Pharmacist

    Helen L. Figge, PharmD, MBA, CPHIMS, FHIMSS Senior Vice President, Global Strategies and Development LumiraDx, USA, Inc. Waltham, Massachusetts Co-Chair, Health 2.0 Boston HIMSS NYS National Liaison Complex neurodegenerative diseases affect millions of Americans and include such conditions as Alzheimer's disease , Parkinson's disease, and amyotrophic lateral sclerosis .

    Comment?

  16. Drug Therapy and Down SyndromeRead the original story

    Jan 17, 2017 | Pharmacy Times

    Down syndrome , also known as trisomy 21, is the most common cause of mental retardation. DS is caused by the presence of an additional 21st chromosome in affected individuals.Patients with DS, especially children, are often on medications to treat various comorbidities that are frequently present.

    Comment?

  17. Alzheimer's advocateRead the original story w/Photo

    Jan 16, 2017 | De Kalb Midweek

    Oestreicher knew that he didn't want to sit idly by, give up and let the disease run its course. Instead, with his wife Marilyn by his side, he is standing up, fighting back and having his voice heard as an advocate for others diagnosed with the disease.

    Comment?

  18. NJ-Based, Minority Woman-Owned Firm Tapped to Promote Alzheimer's...Read the original story

    Jan 10, 2017 | PRWeb

    New Jersey B2B at its best - Impact Consulting Enterprises has signed a deal with Suven, Inc., a Monmouth Junction, N.J.-based pharmaceutical company, to promote the launch of a clinical drug trial for a promising new Alzheimer's disease medication. SUVN-502 could bring hope to millions of Americans living with Alzheimer's disease.

    Comment?

  19. Eisai Company And Keio University To Establish A New Industry-Academia Collaboration SiteRead the original story

    Dec 21, 2016 | BioSpace

    Eisai Co., Ltd. and Keio University announced today that they have entered into a new joint research agreement for the discovery and development of new drugs targeting dementia. For this collaborative research, a research lab will be established, and researchers from Eisai and Keio University will work together to identify and validate novel drug targets and biomarkers that could potentially lead to the development of new therapeutics and preventive medicines for dementia.

    Comment?

  20. Pharnext Presents Positive Exploratory Phase 2 Data From PXT864 at...Read the original story

    Dec 13, 2016 | Customer Interaction Solutions

    Pharnext Presents Positive Exploratory Phase 2 Data From PXT864 at the 9th Clinical Trials on Alzheimer's Disease Conference in San Diego, United States Pharnext Presents Positive Exploratory Phase 2 Data From PXT864 at the 9th Clinical Trials on Alzheimer's Disease Conference in San Diego, United States Pharnext SA , a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, presented positive exploratory Phase 2 data for PXT864, a PLEODRUG being developed for the treatment of Alzheimer's disease , at the 9th Clinical Trials on Alzheimer's Disease conference, on December 8-10, 2016 in San Diego .

    Comment?